ENDPOINTS

BioNTech to acquire CureVac in all-stock deal valued at $1.25B

BioNTech plans to buy mRNA-based cancer immunotherapy and infectious disease vaccine company CureVac in an all-stock deal, the companies said Thursday. The acquisition gives an implied equity value of about ...

Jun 12, 2025 - 12:40
 0
BioNTech to acquire CureVac in all-stock deal valued at $1.25B
BioNTech plans to buy mRNA-based cancer immunotherapy and infectious disease vaccine company CureVac in an all-stock deal, the companies said Thursday. The acquisition gives an implied equity value of about ...
Read More

Tags:

Previous Article

Injured Skin Cells Fire like Neurons to ‘Scream’ for Help

Next Article

nDreams Offers a Deep Dive into Next Level VR Immersion Coming to ‘Reach’

Related Posts

FDA lifts hold on Scynexis trial; Incyte’s Zynyz notches another FDA approval

FDA lifts hold on Scynexis trial; Incyte’s Zynyz notche...

May 16, 2025  0

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

Novo turns to Septerna for oral obesity medicines in de...

May 14, 2025  0

Sanofi pays out two STAT6 milestones; Theravance sells more Trelegy royalties

Sanofi pays out two STAT6 milestones; Theravance sells ...

Jun 2, 2025  0